1
|
Kraus MB, Leuzinger K, Reynolds E, Gallo de Moraes A, Smith J, Sharpe EE, Quillen J, Kosiorek H, Harbell MW. Diabetes insipidus related to sedation in the intensive care unit: A review of the literature. J Crit Care 2023; 75:154233. [PMID: 36738631 DOI: 10.1016/j.jcrc.2022.154233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2022] [Revised: 11/21/2022] [Accepted: 12/09/2022] [Indexed: 02/05/2023]
Abstract
PURPOSE To identify cases of diabetes insipidus (DI) related to sedation in the ICU to determine which medications pose the greatest risk and understand patterns of presentation. MATERIALS AND METHODS We searched PubMed, Embase, Scopus, Google Scholar, and Web of Science. Search terms included "polyuria," "diabetes insipidus," "hypnotics and sedatives," "sedation," as well as individual medications. Case reports or series involving DI or polyuria related to sedation in the ICU were identified. RESULTS We identified 21 cases of diabetes insipidus or polyuria in the ICU attributed to a sedative. Dexmedetomidine was implicated in 42.9% of cases, followed by sevoflurane (33.3%) and ketamine (23.8%). Sevoflurane was implicated in all 7 cases in which it was used (100%; 95% CI 59.0%, 100.0%), dexmedetomidine in 9 of 11 cases (81.8%; 95% CI 48.2, 97.7), and ketamine in 5 of 9 cases (55.6%; 95% CI 21.2%, 86.3%). CONCLUSIONS Awareness of the potential for sedatives to cause DI may lead to greater identification with swifter medication discontinuation and subsequent resolution of DI.
Collapse
Affiliation(s)
- Molly B Kraus
- Anesthesiology, Department of Anesthesiology and Perioperative Medicine, 5777 E Mayo Blvd, Phoenix, AZ 85054, United States of America.
| | - Kahlin Leuzinger
- Anesthesiology, Department of Anesthesiology and Perioperative Medicine, 5777 E Mayo Blvd, Phoenix, AZ 85054, United States of America
| | - Emily Reynolds
- Anesthesiology, Department of Anesthesiology and Perioperative Medicine, 5777 E Mayo Blvd, Phoenix, AZ 85054, United States of America
| | - Alice Gallo de Moraes
- Medicine, Pulmonary and Critical Care Medicine, 200 First St. SW, Rochester, MN 55905, United States of America
| | - Julianna Smith
- Mayo Clinic Alix School of Medicine, 13400 E Shea Blvd, Scottsdale, AZ 85259, United States of America
| | - Emily E Sharpe
- Anesthesiology, Department of Anesthesiology and Perioperative Medicine, 200 First St. SW, Rochester, MN 55905, United States of America
| | - Jaxon Quillen
- Department of Quantitative Health Sciences, 5777 E Mayo Blvd, Phoenix, AZ 85054, United States of America
| | - Heidi Kosiorek
- Department of Quantitative Health Sciences, 5777 E Mayo Blvd, Phoenix, AZ 85054, United States of America
| | - Monica W Harbell
- Anesthesiology, Department of Anesthesiology and Perioperative Medicine, 5777 E Mayo Blvd, Phoenix, AZ 85054, United States of America
| |
Collapse
|
2
|
Nephrogenic Diabetes Insipidus following an Off-Label Administration of Sevoflurane for Prolonged Sedation in a COVID-19 Patient and Possible Influence on Aquaporin-2 Renal Expression. Case Rep Anesthesiol 2022; 2022:3312306. [PMID: 35310519 PMCID: PMC8933092 DOI: 10.1155/2022/3312306] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2022] [Accepted: 02/10/2022] [Indexed: 11/17/2022] Open
Abstract
During the recent COVID-19 pandemic, the rapidly progressive shortage of intravenous sedative drugs led numerous intensive care units to look for potential alternatives in patients requiring mechanical ventilation for severe acute respiratory distress syndrome (ARDS). Inhalational sedation using the AnaConDa® device for sevoflurane administration is a possible option. In a 54-year-old COVID-19 patient with severe ARDS requiring extracorporeal membranous oxygenation (ECMO), sevoflurane on AnaConDa® device was administered for 8 days but was complicated by the development of nephrogenic diabetes insipidus (NDI). Other causes of NDI or central diabetes insipidus were reasonably excluded, as in other previously published cases of NDI in ICU patients receiving prolonged sevoflurane-based sedation. In addition, the postmortem examination suggested a lower expression of aquaporin-2 in renal tubules. This observation should prompt further investigations to elucidate the role of aquaporin-2 in sevoflurane-related NDI. Inhaled isoflurane sedation is a possible alternative.
Collapse
|
3
|
Van Decar LM, Reynolds EG, Sharpe EE, Harbell MW, Kosiorek HE, Kraus MB. Perioperative Diabetes Insipidus Caused by Anesthetic Medications: A Review of the Literature. Anesth Analg 2021; 134:82-89. [PMID: 33410610 DOI: 10.1213/ane.0000000000005344] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Diabetes insipidus (DI) is an uncommon perioperative complication that can occur secondary to medications or surgical manipulation and can cause significant hypovolemia and electrolyte abnormalities. We reviewed and evaluated the current literature and identified 24 cases of DI related to medications commonly used in anesthesia such as propofol, dexmedetomidine, sevoflurane, ketamine, and opioids. This review summarizes the case reports and frequency of DI with each medication and presents possible pathophysiology. Medication-induced DI should be included in the differential diagnosis when intraoperative polyuria is identified. Early identification, removal of the agent, and treatment of intraoperative DI are critical to minimize complications.
Collapse
Affiliation(s)
| | | | - Emily E Sharpe
- Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota
| | - Monica W Harbell
- From the Department of Anesthesiology and Perioperative Medicine
| | - Heidi E Kosiorek
- From the Department of Anesthesiology and Perioperative Medicine.,Department of Health Sciences Research, Mayo Clinic, Phoenix, Arizona
| | - Molly B Kraus
- From the Department of Anesthesiology and Perioperative Medicine
| |
Collapse
|
4
|
Nephrogenic diabetes insipidus associated with prolonged sedation with sevoflurane in the intensive care unit. Br J Anaesth 2019; 122:e73-e75. [PMID: 30916031 DOI: 10.1016/j.bja.2019.02.009] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2018] [Revised: 01/21/2019] [Accepted: 02/07/2019] [Indexed: 11/20/2022] Open
|
5
|
Abstract
The inhaled anaesthetic sevoflurane is metabolised into two products that have the potential to produce renal injury. Fluoride ions are produced by oxidative defluorination of sevoflurane by the cytochrome P450 system in the liver. Until recently, inorganic fluoride has been thought to be the aetiological agent responsible for fluorinated anaesthetic nephrotoxicity, with a toxic concentration threshold of 50 micromol/L in serum. However, studies of sevoflurane administration in animals and humans have not shown evidence of fluoride-induced nephrotoxicity, despite serum fluoride concentrations in this range. Compound A (fluoromethyl-2,2-difluoro-1-[trifluoromethyl] vinyl ether) is a breakdown product of sevoflurane produced by its interaction with carbon dioxide absorbents in the anaesthesia machine. The patient then inhales compound A. Compound A produces evidence of transient renal injury in rats. The mechanism of compound A renal toxicity is controversial, with the debate focused on the role of the renal cysteine conjugate beta-lyase pathway in the biotransformation of compound A. The significance of this debate centres on the fact that the beta-lyase pathway is 10- to 30-fold less active in humans than in rats. Therefore, if biotransformation by this pathway is responsible for the production of nephrotoxic metabolites of compound A, humans may be less susceptible to compound A renal toxicity than are rats. In three studies in human volunteers and one in surgical patients, prolonged (8-hour) sevoflurane exposures and low fresh gas flow rates resulted in significant exposures to compound A. Transient abnormalities were found in biochemical markers of renal injury measured in urine. These studies suggested that sevoflurane can result in renal toxicity, mediated by compound A, under specific circumstances. However, other studies using prolonged sevoflurane administration at low flow rates did not find evidence of renal injury. Finally, there are substantial data to document the safety of sevoflurane administered for shorter durations or at higher fresh gas flow rates. Therefore, the United States Food and Drug Administration recommends the use of sevoflurane with fresh gas flow rates at least 1 L/min for exposures up to 1 hour and at least 2 L/min for exposures greater than 1 hour. We believe this is a rational, cautious approach based on available data. However, it is important to note that other countries have not recommended such limitations on the clinical use of sevoflurane and problems have not been noted.
Collapse
Affiliation(s)
- B A Gentz
- Department of Anesthesiology, The University of Arizona, Tucson, Arizona 85724-5114, USA
| | | |
Collapse
|
6
|
Abstract
Anions are the negative components of most chemical structures and play many important physiological and pharmacological roles that are of interest to the anaesthetist. Their relevance is reviewed with a particular emphasis on the inorganic anions (halides, bicarbonate, phosphate and sulphate) and the significance and limitations of the anion gap. Organic anions (albumin, lactate) are also discussed, albeit briefly. The suitability of anions for their role in neurotransmission and acid-base balance is outlined.
Collapse
Affiliation(s)
- D G Maloney
- Department of Anaesthetics, University Hospital of Wales, Heath Park, Cardiff CF14 4XW, UK.
| | | | | |
Collapse
|
7
|
Higuchi H, Adachi Y, Wada H, Kanno M, Satoh T. The Effects of Low-Flow Sevoflurane and Isoflurane Anesthesia on Renal Function in Patients with Stable Moderate Renal Insufficiency. Anesth Analg 2001. [DOI: 10.1213/00000539-200103000-00019] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
8
|
Higuchi H, Adachi Y, Wada H, Kanno M, Satoh T. The effects of low-flow sevoflurane and isoflurane anesthesia on renal function in patients with stable moderate renal insufficiency. Anesth Analg 2001; 92:650-5. [PMID: 11226095 DOI: 10.1097/00000539-200103000-00019] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
UNLABELLED Sevoflurane degrades to Compound A, which is nephrotoxic in rats. Therefore, the renal effects of Compound A is an area of intense debate. We investigated the effects of low-flow sevoflurane and isoflurane anesthesia on renal function in patients with stable renal insufficiency. Seventeen patients with a serum creatinine level of more than 1.5 mg/dL were anesthetized with sevoflurane or isoflurane at a total flow of 1 L/min. Serum creatinine and blood urea nitrogen were measured before anesthesia and again 1, 2, 3, 5, 7, and 14 days after anesthesia. The 24-h creatinine clearance was measured before anesthesia and 7 days after anesthesia. There were no significant differences in the blood urea nitrogen levels, serum creatinine concentrations, or creatinine clearance before and after anesthesia within each group. These results suggest that sevoflurane and isoflurane have similar effects on renal function in patients with moderately impaired renal function. Further study of the effects of low-flow sevoflurane anesthesia on impaired renal function with a larger sample size than ours is required to resolve the issue of sevoflurane safety in patients with renal insufficiency. IMPLICATIONS The serum creatinine and blood urea nitrogen data indicate that, for exposures of <130 ppm/h in Compound A inspired area under the curve, renal effects of low-flow sevoflurane are similar to those of isoflurane in patients with stable renal insufficiency.
Collapse
Affiliation(s)
- H Higuchi
- Department of Anesthesia, Self Defense Force Central Hospital, Tokyo, Japan.
| | | | | | | | | |
Collapse
|
9
|
Delgado-Herrera L, Ostroff RD, Rogers SA. Sevoflurance: approaching the ideal inhalational anesthetic. a pharmacologic, pharmacoeconomic, and clinical review. CNS DRUG REVIEWS 2001; 7:48-120. [PMID: 11420572 PMCID: PMC6741648 DOI: 10.1111/j.1527-3458.2001.tb00190.x] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Sevoflurane is a safe and versatile inhalational anesthetic compared with currently available agents. Sevoflurane is useful in adults and children for both induction and maintenance of anesthesia in inpatient and outpatient surgery. Of all currently used anesthetics, the physical, pharmacodynamic, and pharmacokinetic properties of sevoflurane come closest to that of the ideal anesthetic (200). These characteristics include inherent stability, low flammability, non-pungent odor, lack of irritation to airway passages, low blood:gas solubility allowing rapid induction of and emergence from anesthesia, minimal cardiovascular and respiratory side effects, minimal end-organ effects, minimal effect on cerebral blood flow, low reactivity with other drugs, and a vapor pressure and boiling point that enables delivery using standard vaporization techniques. As a result, sevoflurane has become one of the most widely used agents in its class.
Collapse
Affiliation(s)
- L Delgado-Herrera
- Abbott Laboratories, Hospital Products Division, 200 Abbott Park Road, Abbott Park, IL 60064, USA.
| | | | | |
Collapse
|
10
|
Nishiyama T, Hanaoka K. Inorganic fluoride kinetics and renal and hepatic function after repeated sevoflurane anesthesia. Anesth Analg 1998; 87:468-73. [PMID: 9706952 DOI: 10.1097/00000539-199808000-00044] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
UNLABELLED After repeated exposure to inhaled anesthetics, the hepatic function and metabolism of anesthetics may change. The purpose of this study was to investigate inorganic fluoride (F-) kinetics and renal and hepatic function after repeated exposure to sevoflurane. Ten patients (aged 40-70 yr) who had received sevoflurane anesthesia with a gas flow of 6 L/min for neurosurgery twice in 30-90 days were studied. Serum and urine F- concentrations were measured up to 24 h after anesthesia. Blood urea nitrogen, serum creatinine, serum and urine beta2-microglobulin, urine N-acetyl-beta-D-glucosaminidase, serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin concentrations were measured up to 7 days after anesthesia. The area under the curve (AUC) of serum and urine F- concentration and half-life of serum F concentration were calculated. Urine beta2-microglobulin, AST, and ALT increased to abnormal levels after both anesthesias, with no difference between anesthesias. No measured variables, AUC of serum and urine F- concentration, or half-life of serum F- concentration showed any differences between the first and second anesthesias. In conclusion, the second exposure to sevoflurane with a high gas flow of 6 L/min in 30-90 days did not change the hepatic and renal function or affect the metabolism of sevoflurane. IMPLICATIONS We studied the changes of metabolism of sevoflurane and hepatic and renal function after repeated sevoflurane anesthesia in 30-90 days. There were changes indicative of mild liver and kidney injury after sevoflurane anesthesia, but repeated exposure to sevoflurane did not enhance these changes.
Collapse
Affiliation(s)
- T Nishiyama
- Department of Anesthesiology, Faculty of Medicine, The University of Tokyo, Japan
| | | |
Collapse
|
11
|
Nishiyama T, Hanaoka K. Inorganic Fluoride Kinetics and Renal and Hepatic Function After Repeated Sevoflurane Anesthesia. Anesth Analg 1998. [DOI: 10.1213/00000539-199808000-00044] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
12
|
Mori N, Nagata H, Ohta S, Suzuki M. Prolonged sevoflurane inhalation was not nephrotoxic in two patients with refractory status asthmaticus. Anesth Analg 1996; 83:189-91. [PMID: 8659736 DOI: 10.1097/00000539-199607000-00035] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
- N Mori
- Department of Anesthesiology, Akita University Hospital, Japan
| | | | | | | |
Collapse
|
13
|
Mori N, Nagata H, Ohta S, Suzuki M. Prolonged Sevoflurane Inhalation Was Not Nephrotoxic in Two Patients with Refractory Status Asthmaticus. Anesth Analg 1996. [DOI: 10.1213/00000539-199607000-00035] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
14
|
Abstract
Several characteristics of sevoflurane biotransformation are apparent from the preceding investigations. Metabolism is rapid, with fluoride and HFIP appearing in plasma within minutes after the start of sevoflurane administration (38-40,51). Peak plasma fluoride concentrations generally occur within approximately 1 h after the termination of sevoflurane administration in most patients, regardless of the dose or duration of exposure (ranging from 0.35-9.5 MAC-h) (39,48). Peak plasma inorganic fluoride concentrations are proportional to sevoflurane dose, measured in MAC-h (42-44). Inorganic fluoride concentrations decline rapidly after termination of sevoflurane administration, with concentrations well below peak levels by the first postoperative day. HFIP is rapidly conjugated, with more than 85% circulating in plasma as the glucuronide. Plasma HFIP concentrations peak later than fluoride concentrations, but both metabolites are eliminated at similar rates (52). Metabolism of sevoflurane does not contribute to the termination of clinical drug effect (52), unlike more extensively metabolized drugs such as halothane (55). Sevoflurane is metabolized by P-450 2E1, so pathophysiologic factors and drug interactions altering P-450 2E1 activity will also influence sevoflurane metabolism (52). The extent of metabolism of sevoflurane, 2% to 5%, is less than that of all other volatile anesthetics except isoflurane and desflurane. It has been proposed that the ideal anesthetic should resist biotransformation because anesthetic toxicity is related to anesthetic metabolism (67,68). Experience to date suggests that biotransformation of sevoflurane has not been causally related to either hepatic or renal toxicity. Sevoflurane does not result in formation of fluoroacetylated liver neoantigens or other reactive metabolites. Although both sevoflurane and methoxyflurane may produce plasma fluoride concentrations in excess of 50 microM, they have not produced the same nephrotoxic effects. Clearly, anesthetic metabolism and anesthetic toxicity can no longer be considered synonymous. The introduction of sevoflurane into clinical practice will hopefully stimulate new investigations into biochemical mechanisms of anesthetic toxicity and continued clinical investigations regarding the relationship between anesthetic metabolism and organ toxicity.
Collapse
Affiliation(s)
- E D Kharasch
- Department of Anesthesiology, University of Washington, Seattle 98195, USA
| |
Collapse
|
15
|
Affiliation(s)
- T P Malan
- Department of Anesthesiology, University of Arizona, Tucson, USA
| |
Collapse
|
16
|
Affiliation(s)
- J G Kenna
- Department of Pharmacology and Toxicology, St. Mary's Hospital Medical School, Imperial College of Science, Technology and Medicine, London, United Kingdom
| | | |
Collapse
|
17
|
Abstract
This article reviews the physico-chemical properties and performance characteristics of the two new potent inhaled anesthetics, desflurane and sevoflurane. Both drugs provide a greater degree of control of anesthetic depth and a more rapid immediate recovery from anesthesia than is currently available with other inhaled agents because of their decreased solubility. Desflurane is currently in widespread clinical use in the United States and parts of Europe. Compared with sevoflurane, it has the additional advantage of being extremely resistant to degradation and biotransformation. However, its pungent odor and tendency to irritate the respiratory tract make it unsuitable for inhalational inductions, and it has been linked to CO production in CO2 absorbents. The sympathetic nervous system activation that occurs with desflurane limits its use in patients with cardiac disease. Otherwise, its hemodynamic and physiologic effects are similar to those seen with isoflurane. Studies of the economics of using desflurane are mixed, although it may offer the advantage of shorter postoperative recovery time. Sevoflurane is currently in widespread clinical use in Japan and parts of South America. The FDA Advisory Panel has recently recommended approval of sevoflurane in the United States, and we can expect the drug to be clinically available in the United States in the second quarter of 1995. Compared with desflurane, sevoflurane has the additional advantage of being nonirritating to the airway; inhalational induction of anesthesia with sevoflurane is achieved rapidly and easily. The instability of sevoflurane with CO2 absorbents and its in vivo biotransformation produce potentially toxic byproducts. These byproducts, including Compound A and fluoride, have been extensively studied, and although the possibility for iatrogenic sequelae from sevoflurane exists, the likelihood of long-term toxicity appears quite low. Phase IV studies are indicated to determine the safety of administering sevoflurane (1) to renally impaired patients and (2) to any patient with fresh gas flows less than 2 L/min. Sevoflurane is otherwise very well tolerated and appears to offer the advantage of rapid and smooth induction and emergence from general anesthesia.
Collapse
Affiliation(s)
- C J Young
- Department of Anesthesia and Critical Care, University of Chicago, IL 60637, USA
| | | |
Collapse
|
18
|
Abstract
Increased duration of anaesthetic administration has implications for recovery from anaesthesia, has cardiovascular effects, and potential for toxicity through metabolism and breakdown of the anaesthetics. Recovery of function after desflurane or sevoflurane anaesthesia, because of the low blood gas and tissue solubilities of these agents, is more rapid than after halothane, isoflurane or enflurane, with recovery being most rapid after desflurane. Increased duration of anaesthesia amplifies the differences in rate of recovery because of the additional anaesthetic (greater with more soluble agents) dissolved in tissues. Increased duration of anaesthesia lessens the cardiovascular depression associated with most halogenated inhaled anaesthetics including desflurane, but not isoflurane. Increased duration of anaesthesia allows for greater metabolism of anaesthetics and greater exposure to metabolites and potentially toxic breakdown products. Desflurane is the least metabolised of the available anaesthetics and is stable in soda lime and Baralyme. Thus, it has exceedingly low potential for toxicity. Sevoflurane undergoes considerable metabolism, producing free fluoride ion, with plasma concentrations proportional to dose and duration of anaesthesia exceeding 50 microM in approximately 7% of patients. In rats, the effects of a toxic breakdown product of sevoflurane, CF2 = C(CF3)OCH2F (compound A), are also dose- and duration-dependent, with lower concentrations producing toxic effects as duration of exposure increases. The clinical importance of the metabolism and in vitro breakdown of sevoflurane has still to be adequately tested.
Collapse
Affiliation(s)
- R B Weiskopf
- Department of Anesthesia, University of California, San Francisco, USA
| |
Collapse
|
19
|
Abstract
Sevoflurane, a methylethylether halogenated solely with fluorine, is characterized by a low blood/gas solubility (blood/gas partition coefficient = 0.65). This feature allows in a more rapid uptake and elimination than with more soluble agents. MAC is about 2 vol% in young adults and 2.5 vol% in children of more than 6 months of age. It undergoes degradation by soda lime in various components. Among them, compound A (an olefin) produces renal toxicity in rats. Total sevoflurane metabolism represents about 5% of inhaled dose and produces inorganic fluorides. However no renal toxic effects has been reported up to now in animals and in patients. The effects on central nervous and cardiovascular systems are close to those of isoflurane. It decreases cerebral vascular resistances and cerebral oxygen consumption, but does not cause convulsive activity. It decreases myocardial contractility, systolic arterial pressure and systemic vascular resistances, but heart rate remains basically unchanged up to 1 MAC. It does not sensitize the myocardium to catecholamines. It depresses ventilation in a dose-dependent fashion, this effect being more pronounced than that of halothane but less than that of both isoflurane and enflurane. It is not irritant for the airways and has some bronchodilatory effect. In adults, recovery is more rapid than with isoflurane. In children, sevoflurane seems a promising agent owing to its good acceptance for mask induction, as well as its favourable haemodynamic profile. However due to its rapid elimination, analgesic drugs should be administered early enough to decrease the incidence of postoperative pain.
Collapse
Affiliation(s)
- I Murat
- Service d'Anesthésie-Réanimation, Hôpital d'Enfants Armand-Trousseau, Paris
| | | | | |
Collapse
|